A Randomized Clinical Trial of a Culturally Tailored Diabetes Education Curriculum With and Without Real-Time Continuous Glucose Monitoring in a Latino Population With Type 2 Diabetes: The CUT-DM With Continuous Glucose Monitoring Study.

J Diabetes Sci TechnolApr 10, 2025 (epub)
Clinical ResearchEndocrinologyOpen access

Nicole Ehrhardt, Laura Montour, Peter Berberian et al.

✦ AI-curated · Sources linked

In 30 seconds

This open-label randomized controlled trial compared culturally tailored diabetes education alone with the same education plus cyclic real-time continuous glucose monitoring (RT-CGM) in 120 Latino adults with uncontrolled type 2 diabetes at a Federally Qualified Health Center. All participants received 12 education sessions; the population was primarily Spanish-preferring and mostly not using insulin. Mean baseline HbA1c was 10.5%. At 12 weeks, HbA1c fell by 2.3% with RT-CGM versus 1.5% with education alone (P =.04). Overall improvement was maintained at 24 weeks, but the between-group difference attenuated.

Key findings

  • HbA1c decreased by 1.9% overall from baseline to 12 weeks (95% confidence interval [CI]: 1.5-2.3; P < .001).
  • At 12 weeks, HbA1c fell by 2.3% (95% CI: 1.5-3.2) with RT-CGM versus 1.5% (95% CI: 0.6-2.3) with blinded CGM (P =.04).
  • At 24 weeks, overall HbA1c reduction was maintained, while the between-group difference attenuated.

Why it matters

The trial suggests that culturally tailored diabetes education can be associated with substantial short-term HbA1c improvement in a Latino population with poorly controlled type 2 diabetes, and that adding RT-CGM may provide additional benefit. The findings are relevant to education and glucose-monitoring approaches for populations often underrepresented in diabetes research, while the attenuated group difference at follow-up underscores uncertainty about durability.

What to keep in mind

Mean attendance was 7.0 of 12 education sessions, and mean RT-CGM wear was 27.9 days. The between-group difference attenuated by 24 weeks.

Source

Published in J Diabetes Sci Technol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.